Organogenesis Holdings, Inc. Investigated by the Portnoy Law Firm
Organogenesis Holdings Inc. - Class A (ORGO)
Last organogenesis holdings inc. - class a earnings: 3/9 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
LOS ANGELES, April 15, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Organogenesis Holdings, Inc. (“Organogenesis" or the "Company") (NASDAQ: ORGO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via http://portnoylaw.com/organogenesis-holdings-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. Organogenesis’s stock price plummeted $0.59 per share, or 10.14%, to close at $5.28 per share on December 30, 2025, thereby injuring investors. This sharp market contraction was triggered by a December 26, 2025, announcement from the Centers for Medicare & Medicaid Services (CMS) regarding a significant shift in the regulatory environme
Show less
Read more
Impact Snapshot
Event Time:
ORGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORGO alerts
High impacting Organogenesis Holdings Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ORGO
News
- Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM [Yahoo! Finance]Yahoo! Finance
- Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AMGlobeNewswire
- Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis PainGlobeNewswire
- Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026GlobeNewswire
- Organogenesis (ORGO) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.MarketBeat
ORGO
Earnings
- 5/8/25 - Miss
ORGO
Sec Filings
- 3/11/26 - Form 4
- 3/11/26 - Form 4
- 3/3/26 - Form 4
- ORGO's page on the SEC website